Velia Bongarzoni

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience

Carmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, Concetta Conticello et autres

it (code pays fourni par la source)

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, Anna Mele et autres

it, gb (code pays fourni par la source)

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Sonia Morè, Massimo Offidani, Laura Corvatta, Tommaso Zà et autres

it, us (code pays fourni par la source)

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

Gabriella Tomei, Sonia Morè, Francesca Di Landro, Velia Bongarzoni et autres

it (code pays fourni par la source)

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Sonia Morè, Massimo Offidani, Laura Corvatta, Silvia Aloisi et autres

it, gb (code pays fourni par la source)

Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, Anna Mele et autres

it, gb (code pays fourni par la source)

Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients

Sonia Morè, Massimo Offidani, Laura Corvatta, Silvia Aloisi et autres

it, my (code pays fourni par la source)

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients

Fortunato Morabito, Enrica Antonia Martino, Mónica Galli, Massimo Offidani et autres

it (code pays fourni par la source)

Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data

Enrica Antonia Martino, Annalisa Pitino, Massimo Offidani, Roberta Della Pepa et autres

it, jp, us, gr, gb (code pays fourni par la source)

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni et autres

it (code pays fourni par la source)

Long-Term Survival with Multiple Myeloma: An Italian Experience

Francesca Fazio, Martina Gherardini, Elena Rossi, Tommaso Zà et autres

it (code pays fourni par la source)

Author response for "Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study"

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Paola Stefanoni et autres